[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carbonic-anhydrase-ix\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carbonic-anhydrase-ix":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100589571","exploring-the-clinical-application-value-of-caix-targeted-pet-imaging-in-renal-cancer-patients-100589571",false,"NCT06956144","Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients","Inclusion Criteria:\n\n1. Voluntary participation with the patient or their legal representative able to sign the informed consent form.\n2. Adult patients (age between 18 and 75 years), regardless of gender.\n3. Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).\n4. Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.\n5. ECOG performance status score of 0-3.\n6. Laboratory parameters must meet the following criteria:\n\n   1. ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.\n   2. Hematological parameters: 2 x 10\\^9\u002FL ≤ WBC ≤ 2 x 10\\^10\u002FL, PLT ≥ 80 x 10\\^9\u002FL, Hb ≥ 80 g\u002FL.\n7. Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).\n2. Patients or their legal representatives who are unable or unwilling to sign the informed consent form.\n3. Acute systemic diseases and electrolyte imbalances.\n4. Patients unable to complete the PET\u002FCT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).\n5. Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.",true,"ALL","18 Years","74 Years",{"count":20,"type":21},113,"ESTIMATED","OBSERVATIONAL","To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.",[25,26],"Tumor","Carbonic Anhydrase IX",[28,29,30,31],"PET","CAIX","Renal Cancer","diagnosis","RECRUITING","2025-05-27",{"date":35,"type":36},"2025-05-29","ACTUAL",{"date":38,"type":36},"2025-05-09",{"date":40,"type":21},"2026-09-30",{"name":42,"class":43},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100556028","68ga-c1-pet-ct-imaging-in-clear-cell-renal-cell-carcinoma-100556028","NCT06519760","68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma","Evaluation of Diagnostic Value of 68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Signed written informed consent；\n2. Age ≥18；\n3. Patients with confirmed or suspected clear cell renal cell carcinoma;\n4. Expected survival ≥6 months.\n\nExclusion Criteria:\n\n1. Renal mass is known to be a metastasis of another primary tumor;\n2. Have other malignancies that require treatment;\n3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;\n4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin\u002F1.73 m²;\n5. Pregnant and lactating women or female patients plan to become pregnant within 6 months;\n6. Uncontrolled psychiatric disorders;\n7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).",{"count":53,"type":21},200,"INTERVENTIONAL",[56],"NA","The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET\u002FCT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1.\n\nResearchers will compare the diagnostic value of 68Ga-C1 PET\u002FCT and 18F-FDG PET\u002FCT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.",[26,59,60],"PET-CT","Clear Cell Renal Cell Carcinoma",[26,62,59,60],"68Ga-C1","2024-11-05",{"date":65,"type":36},"2024-11-07",{"date":67,"type":36},"2024-07-30",{"date":69,"type":21},"2026-12-31",{"name":71,"class":43},"Peking University First Hospital"]